1,741 results match your criteria Nature Reviews Neurology[Journal]


Oligodendrocyte studies reveal limits on remyelination.

Authors:
Ian Fyfe

Nat Rev Neurol 2019 Feb 12. Epub 2019 Feb 12.

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0149-5DOI Listing
February 2019

Author Correction: Protecting the ischaemic penumbra as an adjunct to thrombectomy for acute stroke.

Nat Rev Neurol 2019 Feb 11. Epub 2019 Feb 11.

Department of Neurology, Hôpital Sainte- Anne, Université Paris 5, INSERM U894, Paris, France.

The originally published article contained an error in Table 1, whereby the RESCUE trial appeared on the "Transient descending aortic balloon occlusion (TAO)" line instead of the "Remote ischaemic perconditioning (RIPerC)" line. This has been corrected in the HTML and PDF versions of the manuscript. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0148-6DOI Listing
February 2019

Dementia in Down syndrome: unique insights for Alzheimer disease research.

Nat Rev Neurol 2019 Feb 7. Epub 2019 Feb 7.

Sanders Brown Center on Aging, University of Kentucky, Lexington, KY, USA.

Virtually all adults with Down syndrome (DS) show the neuropathological changes of Alzheimer disease (AD) by the age of 40 years. This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21. Amyloid-β accumulates in the brain across the lifespan of people with DS, which provides a unique opportunity to understand the temporal progression of AD and the epigenetic factors that contribute to the age of dementia onset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0132-6DOI Listing
February 2019

Defects in adenosine metabolism identified in ALS.

Authors:
Heather Wood

Nat Rev Neurol 2019 Feb 7. Epub 2019 Feb 7.

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0147-7DOI Listing
February 2019

Lifestyle factors and progression of PD.

Authors:
Rebecca Kelsey

Nat Rev Neurol 2019 Feb 4. Epub 2019 Feb 4.

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0144-xDOI Listing
February 2019

Gene editing shows promise in LCA10.

Authors:
Rebecca Kelsey

Nat Rev Neurol 2019 Feb 4. Epub 2019 Feb 4.

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0143-yDOI Listing
February 2019

Prolonging the integrated stress response could be beneficial in multiple sclerosis.

Authors:
Rebecca Kelsey

Nat Rev Neurol 2019 Feb 4. Epub 2019 Feb 4.

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0142-zDOI Listing
February 2019
1 Read

CGRP antibodies for migraine prevention - new kids on the block.

Nat Rev Neurol 2019 Feb 1. Epub 2019 Feb 1.

Faculty of Medicine, University Duisburg-Essen, Essen, Germany.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-019-0139-7
Publisher Site
http://dx.doi.org/10.1038/s41582-019-0139-7DOI Listing
February 2019
2 Reads

Stroke trial drug is effective in Alzheimer disease mouse model.

Authors:
Ian Fyfe

Nat Rev Neurol 2019 Feb 1. Epub 2019 Feb 1.

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0141-0DOI Listing
February 2019

The role of sensory information in the pathophysiology of focal dystonias.

Nat Rev Neurol 2019 Jan 30. Epub 2019 Jan 30.

IRCCS Neuromed, Pozzilli, Italy.

Over the past few decades, abnormalities in sensory functions, such as tactile, proprioceptive and nociceptive processing, have been increasingly recognized in patients with focal dystonias. In this Review, we ask whether sensory system abnormalities are specific to particular types of dystonia, whether a causal link exists between sensory alterations and dystonic motor activity and how mechanisms underlying the sensory abnormalities fit in with the proposed 'network model' of dystonia. We suggest that alterations in the various sensory modalities participate at three different levels in the pathophysiological cascade that leads to dystonia: a background level that predisposes individuals to dystonia, a disease-related level that is evident only when dystonia becomes manifest and a causative level that triggers dystonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0137-9DOI Listing
January 2019

Exosomes - beyond stem cells for restorative therapy in stroke and neurological injury.

Nat Rev Neurol 2019 Jan 30. Epub 2019 Jan 30.

Department of Neurology, Henry Ford Hospital, Detroit, MI, USA.

Stroke is a leading cause of disability worldwide, and brain injuries devastate patients and their families, but currently no drugs on the market promote neurological recovery. Limited spontaneous recovery of function as a result of brain remodelling after stroke or injury does occur, and cell-based therapies have been used to promote these endogenous processes. Increasing evidence is demonstrating that the positive effects of such cell-based therapy are mediated by exosomes released from the administered cells and that the microRNA cargo in these exosomes is largely responsible for the therapeutic effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0126-4DOI Listing
January 2019

Decreased NREM sleep linked with tauopathy.

Authors:
Rebecca Kelsey

Nat Rev Neurol 2019 Jan 30. Epub 2019 Jan 30.

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0140-1DOI Listing
January 2019

Deep brain stimulation: current challenges and future directions.

Nat Rev Neurol 2019 Jan 25. Epub 2019 Jan 25.

Department of Neurosurgery, Hannover Medical School, Hannover, Germany.

The clinical use of deep brain stimulation (DBS) is among the most important advances in the clinical neurosciences in the past two decades. As a surgical tool, DBS can directly measure pathological brain activity and can deliver adjustable stimulation for therapeutic effect in neurological and psychiatric disorders correlated with dysfunctional circuitry. The development of DBS has opened new opportunities to access and interrogate malfunctioning brain circuits and to test the therapeutic potential of regulating the output of these circuits in a broad range of disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0128-2DOI Listing
January 2019
2 Reads
15.358 Impact Factor

Chronic traumatic encephalopathy - confusion and controversies.

Nat Rev Neurol 2019 Jan 21. Epub 2019 Jan 21.

Department of Neuropathology, Queen Elizabeth University Hospital, Glasgow, UK.

The term chronic traumatic encephalopathy (CTE) has recently entered public consciousness via media reports and even a Hollywood movie. However, in contrast to general impressions, the incidence of CTE is unknown, the clinical diagnostic criteria have not been agreed upon and the current neuropathological characterization of CTE is acknowledged as preliminary. Additionally, few studies have compared the pathologies of CTE with those of other neurodegenerative disorders or of age-matched controls. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0114-8
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0114-8DOI Listing
January 2019
5 Reads

Getting closer to a cure for migraine.

Nat Rev Neurol 2019 Feb;15(2):64-65

Headache Science Center, IRCCS Mondino Foundation, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0134-zDOI Listing
February 2019
1 Read

New therapeutic developments for Parkinson disease.

Nat Rev Neurol 2019 Feb;15(2):68-69

Department of Neurology, Academic Medical Center, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0133-0DOI Listing
February 2019
6 Reads

Personalized vaccines use tumour fingerprint to target glioblastoma.

Authors:
Charlotte Ridler

Nat Rev Neurol 2019 Feb;15(2):59

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0135-yDOI Listing
February 2019
2 Reads

Stroke management - recent advances and residual challenges.

Authors:
Bo Norrving

Nat Rev Neurol 2019 Feb;15(2):69-71

Department of Clinical Sciences Lund, Neurology, Skåne University Hospital, Lund University, Lund, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0129-1DOI Listing
February 2019
1 Read

Bad news and good news in AD, and how to reconcile them.

Authors:
David S Knopman

Nat Rev Neurol 2019 Feb;15(2):61-62

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0131-7DOI Listing
February 2019
1 Read

Teamwork aids management and raises new issues in epilepsy.

Authors:
Dong Zhou

Nat Rev Neurol 2019 Feb;15(2):66-67

Department of Neurology, West China Hospital, Chengdu, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0130-8DOI Listing
February 2019
1 Read

Targeting progression in multiple sclerosis - an update.

Nat Rev Neurol 2019 Feb;15(2):62-64

Neuroimaging Research Unit and Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, Scientific Institute and University Hospital San Raffaele, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0127-3DOI Listing
February 2019
1 Read

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.

Nat Rev Neurol 2019 Feb;15(2):73-88

Department of Research and Development, Chiesi Farmaceutici, Parma, Italy.

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the Alzheimer disease (AD) process. Aβ accumulation begins 15-20 years before clinical symptoms occur, mainly owing to defective brain clearance of the peptide. Over the past 20 years, we have seen intensive efforts to decrease the levels of Aβ monomers, oligomers, aggregates and plaques using compounds that decrease production, antagonize aggregation or increase brain clearance of Aβ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0116-6DOI Listing
February 2019
1 Read
15.358 Impact Factor

Sleep apnoea and poor sleep quality in patients with chronic migraine.

Authors:
Min Kyung Chu

Nat Rev Neurol 2019 Jan 4. Epub 2019 Jan 4.

Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0124-6DOI Listing
January 2019
1 Read

Amyloid-β 'seeds' found in archived vials of growth hormone.

Authors:
Heather Wood

Nat Rev Neurol 2019 Feb;15(2):60

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0125-5DOI Listing
February 2019
1 Read

Immunotherapy in myasthenia gravis in the era of biologics.

Nat Rev Neurol 2019 Feb;15(2):113-124

Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.

No consensus has been reached on the ideal therapeutic algorithm for myasthenia gravis (MG). Most patients with MG require induction therapy with high doses of corticosteroids and maintenance with an immunosuppressant. Severe cases and acute worsening require intravenous immunoglobulin or plasmapheresis before oral immunosuppressants start having an effect. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0110-z
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0110-zDOI Listing
February 2019
13 Reads

APOE*ε4 links exosomes to cognitive decline.

Authors:
Ian Fyfe

Nat Rev Neurol 2019 Feb;15(2):60

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0123-7DOI Listing
February 2019
1 Read

Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Nat Rev Neurol 2019 Feb;15(2):89-102

Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (MOG-Abs) were first detected by immunoblot and enzyme-linked immunosorbent assay nearly 30 years ago, but their association with multiple sclerosis (MS) was not specific. Use of cell-based assays with native MOG as the substrate enabled identification of a group of MOG-Ab-positive patients with demyelinating phenotypes. Initially, MOG-Abs were reported in children with acute disseminated encephalomyelitis (ADEM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0112-xDOI Listing
February 2019
3 Reads

Dementia with Lewy bodies - from scientific knowledge to clinical insights.

Nat Rev Neurol 2019 Feb;15(2):103-112

Windsor Unit, Cambridgeshire and Peterborough NHS Foundation Trust, Fulbourn Hospital, Fulbourn, Cambridge, UK.

Dementia with Lewy bodies (DLB) is the underlying aetiology of 10-15% of all cases of dementia and as such is a clinically important diagnosis. In the past few years, substantial advances have been made in understanding the genetics and pathology of this condition. For example, research has expanded our knowledge of the proteinaceous inclusions that characterize the disease, has provided an appreciation of the role of disease-associated processes such as inflammation and has revealed an association between DLB and genes such as GBA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0107-7DOI Listing
February 2019
2 Reads

Genetic drivers of cerebral blood flow dysfunction in TBI: a speculative synthesis.

Nat Rev Neurol 2019 Jan;15(1):25-39

Division of Anaesthesia, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.

Cerebral autoregulatory dysfunction after traumatic brain injury (TBI) is strongly linked to poor global outcome in patients at 6 months after injury. However, our understanding of the drivers of this dysfunction is limited. Genetic variation among individuals within a population gives rise to single-nucleotide polymorphisms (SNPs) that have the potential to influence a given patient's cerebrovascular response to an injury. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0105-9
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0105-9DOI Listing
January 2019
17 Reads

Intraneuronal implants enable long-term tactile sensation in patients with hand amputation.

Authors:
Charlotte Ridler

Nat Rev Neurol 2019 Jan;15(1)

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0122-8DOI Listing
January 2019
1 Read

Neurophysiological and olfactory biomarkers for multiple sclerosis.

Authors:
Heather Wood

Nat Rev Neurol 2019 Jan;15(1)

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0119-3DOI Listing
January 2019
1 Read

Nature and implications of sex differences in AD pathology.

Nat Rev Neurol 2019 Jan;15(1):6-8

Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0115-7DOI Listing
January 2019
2 Reads

Parkinson disease gene therapy rewires brain circuits to improve motor function.

Authors:
Charlotte Ridler

Nat Rev Neurol 2019 Jan;15(1)

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0120-xDOI Listing
January 2019
1 Read

Sleep deprivation promotes tauopathy in mice.

Authors:
Charlotte Ridler

Nat Rev Neurol 2019 Jan;15(1)

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0121-9DOI Listing
January 2019
1 Read

Olfactory and other sensory impairments in Alzheimer disease.

Authors:
Claire Murphy

Nat Rev Neurol 2019 Jan;15(1):11-24

Department of Psychology, San Diego State University, San Diego, CA, USA.

The vast increase in Alzheimer disease (AD) worldwide has grave implications for individuals, family support systems and the health-care systems that will attempt to cope with the disease. Early markers of the disease are essential for efficient selection of clinical trial participants for drug development and for timely treatment once an intervention becomes available. There is avid interest in noninvasive, inexpensive markers that have the potential to identify prodromal AD. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0097-5
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0097-5DOI Listing
January 2019
2 Reads

Could HIV drugs treat AD?

Authors:
Ian Fyfe

Nat Rev Neurol 2019 Jan;15(1)

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0118-4DOI Listing
January 2019
1 Read

First genetic risk loci for ADHD identified.

Authors:
Charlotte Ridler

Nat Rev Neurol 2019 Jan;15(1)

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0117-5DOI Listing
January 2019
1 Read

Oligodendrocytes - active accomplices in MS pathogenesis?

Authors:
Charlotte Ridler

Nat Rev Neurol 2019 Jan;15(1)

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0111-yDOI Listing
January 2019
1 Read

New in vivo model provides insights into Down syndrome.

Authors:
Heather Wood

Nat Rev Neurol 2019 Jan;15(1):2-3

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0113-9DOI Listing
January 2019
1 Read

How safe is switching antiepileptic drug manufacturers?

Authors:
Martin Holtkamp

Nat Rev Neurol 2019 Jan;15(1):8-9

Epilepsy-Center Berlin-Brandenburg, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0108-6DOI Listing
January 2019
1 Read

A clinically useful MRI marker of PD?

Authors:
Ian Fyfe

Nat Rev Neurol 2019 Jan;15(1):2-3

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0109-5DOI Listing
January 2019
1 Read

POLG-related disorders and their neurological manifestations.

Nat Rev Neurol 2019 Jan;15(1):40-52

Mitochondrial DNA Replication Group, Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Durham, NC, USA.

The POLG gene encodes the mitochondrial DNA polymerase that is responsible for replication of the mitochondrial genome. Mutations in POLG can cause early childhood mitochondrial DNA (mtDNA) depletion syndromes or later-onset syndromes arising from mtDNA deletions. POLG mutations are the most common cause of inherited mitochondrial disorders, with as many as 2% of the population carrying these mutations. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0101-0
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0101-0DOI Listing
January 2019
10 Reads

The role of thymic tolerance in CNS autoimmune disease.

Nat Rev Neurol 2018 Dec;14(12):723-734

Paediatric Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.

The contributions of the peripheral adaptive and innate immune systems to CNS autoimmunity have been extensively studied. However, the role of thymic selection in these conditions is much less well understood. The thymus is the primary lymphoid organ for the generation of T cells; thymic mechanisms ensure that cells with an overt autoreactive specificity are eliminated before they emigrate to the periphery and control the generation of thymic regulatory T cells. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0095-7
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0095-7DOI Listing
December 2018
10 Reads

Genetics influences development of AD pathology.

Authors:
Ian Fyfe

Nat Rev Neurol 2018 Dec;14(12):689

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0106-8DOI Listing
December 2018
1 Read

Biological insights from the premonitory symptoms of migraine.

Nat Rev Neurol 2018 Dec;14(12):699-710

Headache Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Migraine is a common neurological disorder with a diverse clinical phenotype that comprises more than just head pain. Premonitory (prodromal) symptoms can start hours to days before the onset of a migraine headache and can predict its onset in some individuals. Such symptomatology can include lethargy, yawning, light and sound sensitivity, thirst and cravings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0098-4DOI Listing
December 2018
1 Read

From molecules to medicines: the dawn of targeted therapies for genetic epilepsies.

Nat Rev Neurol 2018 Dec;14(12):735-745

Departments of Pediatrics and Neurology, University of Colorado School of Medicine, Aurora, CO, USA.

Precision medicine is the treatment of patients with therapy targeted to their specific pathophysiology. This lofty ideal currently has limited application in clinical practice. However, new technological advances in epilepsy models and genomics suggest that the precision medicine revolution is closer than ever before. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0099-3
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0099-3DOI Listing
December 2018
17 Reads

Amyotrophic lateral sclerosis - a multisystem neurodegenerative disorder.

Authors:
Murray Grossman

Nat Rev Neurol 2019 Jan;15(1):5-6

Penn Frontotemporal Degeneration Center and Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0103-y
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0103-yDOI Listing
January 2019
12 Reads

Author Correction: Neuroimmune disorders of the central nervous system in children in the molecular era.

Nat Rev Neurol 2018 Dec;14(12):749

Department of Neurology and Pediatric Multiple Sclerosis Clinic, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

In the original version of this Review published online and in print, the contribution of attendees of the International Neuroimmune Meeting to the content of the Review was not acknowledged. The author list has been corrected in the PDF and HTML versions of this article to acknowledge that the Review was written on behalf of attendees of the International Neuroimmune Meeting, and the names of the attendees have been added to the HTML version. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0077-9
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0077-9DOI Listing
December 2018
3 Reads

Erenumab succeeds in alleviating migraine where other treatments fail.

Authors:
Charlotte Ridler

Nat Rev Neurol 2018 Dec;14(12):691

Nature Reviews Neurology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-018-0104-xDOI Listing
December 2018
1 Read